TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04360629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid will be given through central vein

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic Acid will be given through central vein

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline will be given through central vein
Study: NCT01634217

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iTreg
Description: The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iTreg
Description: The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
Study: NCT02743169

Intervention type: OTHER
Intervention: Spatially-Optimized
Description: Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
Study: NCT01174082

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Vaccine
Description: Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH Vaccine
Description: Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH-id Vaccine
Description: Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KLH-id Vaccine
Description: Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.~Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m2 subcutaneously daily for 4 days after each vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m2 subcutaneously daily for 4 days after each vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m2 subcutaneously daily for 4 days after each vaccine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/m2 subcutaneously daily for 4 days after each vaccine
Study: NCT03935607

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal sonography
Description: Transvaginal sonography for the evaluation of an amniotic fluid pocket preceding the fetal presenting part.
Study: NCT01174082

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Apheresis
Description: Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Day 0, infusion to patient of collected donor cells.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Donor Lymphocyte Infusion (DLI)
Description: Day 0, infusion to patient of collected donor cells.
Study: NCT04378517

Intervention type: OTHER
Group type: OTHER
Intervention: psychosocial education in parents groups
Description: psychosocial education

Intervention type: OTHER
Group type: OTHER
Intervention: psychosocial parents support, interviews with APN
Description: Family strength-oriented therapy conversation
Study: NCT02756936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir Zeta
Description: 1 tablet contains 60 mg Daclatasvir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clatazev
Description: 1 tablet contains 60 mg Daclatasvir
Study: NCT02880657

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SODB®
Description: Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
Study: NCT02068521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somavaratan
Description: Subcutaneous injection
Study: NCT03407430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: During the first chemotherapy cycle, the patient will receive pregabalin 75mg (1 capsule) BID x 4 days before pegfilgrastim 6mg subcutaneous (SC) x1; then pregabalin 150mg (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive placebo in the same dosing scheme.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: During the first chemotherapy cycle, the patient will receive placebo (1 capsule) BID x 4 days before pegfilgrastim 6mg SC x1; then placebo (2 capsules) BID x 7 days. During the second chemotherapy cycle, the patient will receive pregabalin in the same dosing scheme.
Study: NCT01570283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 1
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 1
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level One: 5x10\^6 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 2
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 2
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Two: 1x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL
Study: NCT01086696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPAC
Description: Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPAC
Description: Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
Study: NCT02809885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis E serology
Study: NCT00900497

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: White Blood Cells/Granulocytes
Description: Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
Study: NCT02298959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Elastography
Description: Undergo MRI

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ziv-Aflibercept
Description: Given IV
Study: NCT03170518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Description: Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Description: Canagliflozin 300 mg tablet will be administered orally once-daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally once-daily.
Study: NCT01570283

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 3
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivirus-specific T cells Dose Level 3
Description: The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.~Dose Level Three: 2x10\^7 mCTLs/m2~There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL
Study: NCT03170518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo tablet will be administered orally once-daily.
Study: NCT02140866

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Compensatory Intervention Program (CIP)
Study: NCT03947736

Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA was detected by dPCR
Description: Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.

Intervention type: DIAGNOSTIC_TEST
Intervention: cfDNA was detected by dPCR
Description: Without drug intervention, the patient's peripheral blood was collected and cfDNA was extracted for digital PCR detection.
Study: NCT01672944

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TBCCN-developed educational materials
Description: Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.

Intervention type: OTHER
Group type: OTHER
Intervention: NCI-developed educational materials
Description: Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica.
Study: NCT01856361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Angiotensin Converting Enzyme Inhibitor

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: Placebo pill that will match the treatment pill
Study: NCT05296213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride- potassium iodide
Description: SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
Study: NCT01298401

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ganitumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study: NCT01224886

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Supervised exercise intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Supervised exercise intervention
Study: NCT01298401

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study: NCT02216318

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blue light

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: blue light
Study: NCT02418143

Intervention type: DEVICE
Intervention: CorMatrix CanGaroo ECM Envelope
Description: Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
Study: NCT02969993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: evaluating the voice outcome by the fullfilment of the voice handicap index
Study: NCT02251691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Compare the drug compliance between once daily or twice daily regimen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prograf
Description: Compare the drug compliance between once daily or twice daily regimen
Study: NCT02496819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meta-cognitive self-regulated learning intervention
Description: It is a 12-week intervention programme with one 60 minutes sessions per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory integration intervention
Description: It is a 12-week intervention programme with one 60 minutes sessions per week.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activity-based intervention
Description: It is a 12-week intervention programme with one 60 minutes sessions per week.
Study: NCT03828136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novum Vitrium® Cervical Interbody Device
Description: For spinal fusion procedure at one level (C3 to T1) of the cervical spine.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allograft Ring or Block
Description: Standard of Care
Study: NCT03090997

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin C (500 mg / day) + placebo
Description: Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: resveratrol (500 mg / day) + placebo
Description: Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
Study: NCT01643460

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 98% Ethanol & Paclitaxel injection
Description: Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size \& amount of fluid aspirated from the cyst.
Study: NCT05296213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium phosphate
Description: CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: experimental tricalcium silicate
Description: prepared tricalcium silicate paste was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
Study: NCT03308292

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Aerobic exercise program
Study: NCT00371787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Soft contact lens
Description: Soft contact lens
Study: NCT01240434

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trocar site closure
Description: The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).

Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Trocar site closure
Description: The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
Study: NCT00972075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin (Circadin)
Description: 2 mg prolonged release melatonin tablets once daily 2 hours before going to bed

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet per day 2 hours before going to bed
Study: NCT00919594

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy for Mothers (IPT-MOMS)
Description: Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Supportive Psychotherapy
Description: Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
Study: NCT00687856

Intervention type: PROCEDURE
Intervention: Echocardiogram (echo)
Description: Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
Study: NCT01418794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High dose rapamycin stent
Description: Concentration of rapamycin is 2.5%

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low dose rapamycin stent
Description: Concentration of rapamycin is 1.5%
Study: NCT01470508

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with Family Enhancement
Description: Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.